Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56405 | 1.00 | TDP1 (0.53) | TDP1LMNACASP3ALDH1A1HTT | |
| SCHEMBL1892274 | 0.84 | TDP1 (0.55) | TDP1LMNACASP3ALDH1A1HTT | |
| SCHEMBL17916019 | 0.83 | TDP1 (0.50) | TDP1LMNACASP3ALDH1A1HTT | |
| SCHEMBL6656473 | 0.81 | TDP1 (0.57) | TDP1LMNACASP3ALDH1A1HTT | |
| SCHEMBL29381145 | 0.81 | TDP1 (0.57) | TDP1LMNACASP3ALDH1A1HTT | |
| SCHEMBL166122 | 0.81 | TDP1 (0.57) | TDP1LMNACASP3ALDH1A1HTT | |
| SCHEMBL2247257 | 0.81 | TDP1 (0.49) | TDP1LMNACASP3ALDH1A1HTT | |
| SCHEMBL9237832 | 0.81 | TDP1 (0.49) | TDP1LMNACASP3ALDH1A1HTT | |
| SCHEMBL1256984 | 0.78 | TDP1 (0.46) | TDP1LMNACASP3ALDH1A1HTT | |
| SCHEMBL4197298 | 0.77 | LMNA (0.56) | TDP1LMNACASP3ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2751141-B1 | STABLE PEPTIDE-BASED PACE4 INHIBITORS | SOCPRA SCIENCES SANTE ET HUMAINES S E C (CA) | 2018-03-21 | — | — | EP | disclosed |
| US-20150148334-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2015-05-28 | — | — | US | disclosed |
| US-8765746-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120214794-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| CN-1086214-A | Di-and triazinedione | MERCK PATENT GMBH (DE) | 1994-05-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148334-A1 | HETEROARYLS AND USES THEREOF | RICTOR, AKT2, MTOR | TDP1 3108/4885LMNA 1127/4885CASP3 516/4885 |
| US-20120214794-A1 | HETEROARYLS AND USES THEREOF | RICTOR, AKT2, MTOR | TDP1 3108/4885LMNA 1127/4885CASP3 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.